Editorial Board About Us

Benign prostatic hyperplasia

All articles from this key word are listed below.

Volume 7, Supplement 8 Review Articles

BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia

Shahrokh F Shariat Eduardo I Canto Kevin M Slawin

Benign prostatic hyperplasia Prostate-specific antigen Free prostate-specificantigen Prostate volume Disease progression

Volume 7, Supplement 4 Review Articles

Summary of Clinical Experiences With Tamsulosin for the Treatment of Benign Prostatic Hyperplasia

Franklin C Lowe

Benign prostatic hyperplasia Tamsulosin Alpha-adrenergic-receptor antagonist

Volume 7, Supplement 4 Review Articles

Is There a Role for a-Blockers for the Treatment of Voiding Dysfunction Unrelated to Benign Prostatic Hyperplasia?

Benign prostatic hyperplasia Lower urinary tract symptoms Alpha-adrenore-

Volume 7, Supplement 4 Review Articles

Long-Term Efficacy and Safety of Tamsulosin for Benign Prostatic Hyperplasia

Perinchery Narayan Hari Siva Gurunadha Rao Tunuguntla

Benign prostatic hyperplasia Tamsulosin Blockers AUA symptom score

Volume 7, Supplement 4 Review Articles

Acute Urinary Retention: Risks and Management

Claus G Roehrborn

Benign prostatic hyperplasia Transurethral resection Acute urinary retention

Volume 7, Supplement 4 Review Articles

Pathophysiology of Benign Prostatic Hyperplasia in the Aging Male Population

Benign prostatic hyperplasia Lower urinary tract symptoms Bladder outlet

Volume 7, Number 1 Meeting Reviews

What's New in Prostate Cancer, Benign Prostatic Hyperplasia, and Minimally Invasive Surgery?

Amir Kaisary Michael Dobrovits Theodore Anagnostou Mesut Remzi Yan Kit Fong Bob Djavan

Prostate cancer Benign prostatic hyperplasia Medical treatment Surgical treatment Minimally invasive surgery Percutaneous surgery

Volume 7, Number 1 Review Articles

Validity of the "Bother Score" in the Evaluation and Treatment of Symptomatic Benign Prostatic Hyperplasia

Michael P O'Leary

Benign prostatic hyperplasia Lower urinary tract symptoms Quality of life

Volume 8, Supplement 4 Review Articles

The Evolution of Alpha-Blockers for the Treatment of Benign Prostatic Hyperplasia

Advances in Alpha-Blocker Therapy in the Management of Urological Disorders

Alpha-blockers have been evaluated for the treatment of benign prostatic hyperplasia (BPH) for 30 years, from early trials with the nonselective a-inhibitor phenoxybenzamine to short-acting (prazosin) then long-acting (terazosin, doxazosin, tamsulosin, alfuzosin) selective a1-antagonists. All of the a-blockers evaluated have demonstrated comparable effectiveness, and the evolution of a-blocker therapy for BPH has therefore focused primarily on improving convenience and tolerability. Although all of the long-acting a1-blockers are well tolerated, only tamsulosin and alfuzosin SR are administered without the requirement for dose titration. Alfuzosin has the additional advantage over tamsulosin of a lower incidence of ejaculatory dysfunction. Studies of subtype-selective a1-antagonists have not demonstrated superior efficacy or improved tolerability over the existing long-acting a1-blockers. [Rev Urol. 2006;8(suppl 4):S3-S9]

Benign prostatic hyperplasia Blockers Lower urinary

Volume 8, Supplement 4 Review Articles

Update on the American Urological Association Guidelines for the Treatment of Benign Prostatic Hyperplasia

Advances in Alpha-Blocker Therapy in the Management of Urological Disorders

Steven A Kaplan

The updated 2003 American Urological Association (AUA) Guidelines for the treatment of benign prostatic hyperplasia (BPH) are the culmination of an exhaustive effort predicated on scientifically accepted methods of reviewing the medical literature. In this second publication of the guidelines, a multidisciplinary panel reviewed a new meta-analysis of outcome data from the BPH literature from before and after 1994. The major differences between the 2 guidelines are the changes in our understanding of the biology of the prostate and the introduction of new therapies. The vast majority of randomized controlled trials, particularly with respect to minimally invasive therapies and progression of BPH, were performed after the release of the 1994 guidelines. Also, the most recent AUA panel carefully reviewed unpublished data to make the guidelines as timely as possible. Studies that were subsequently published included those on the value of combination medical therapy for BPH. The panel agreed on updated recommendations for the treatment of moderate-to-severe lower urinary tract symptoms associated with BPH, and diagnostic algorithms were revised. The durability and utility of the present guidelines should exceed that of its predecessor. [Rev Urol. 2006;8(suppl 4):S10-S17]

Benign prostatic hyperplasia Lower urinary tract symptoms Combination therapy 5-reductase inhibitors AUA Guidelines AUA Symptom Scores